Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Open-Label Basket Study to Evaluate Safety and Pharmacokinetics of INF904, an Oral C5aR1 Inhibitor, in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

NCT06555328 is registered in ClinicalTrials.gov with InflaRx GmbH as lead sponsor.

NCT NCT06555328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06555328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Open-Label Basket Study to Evaluate Safety and Pharmacokinetics of INF904, an Oral C5aR1 Inhibitor, in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
Lead sponsor
InflaRx GmbH
Phase
Phase 2
Overall status
Terminated
Start date
January 2, 2025
Completion date
January 22, 2026
Enrollment
73 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

chronic urticaria, idiopathic, hidradenitis, hidradenitis suppurativa